BioSpace News Archive

NiTiNOL-based device implanted in subtalar fusions

“We can look back on a very strong quarter in which Group sales grew by a significant 22 percent adjusted for currency, driven in particular by Integrated Solutions, whose sales adjusted for currency rose by a remarkable 45 percent.

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00 AM Eastern time. Agenda 2019-nCOV coronavirus initiatives 5/2 dividends in Generex and NuGenerex Immuno-Oncology ALTuCELL Closing S1 funding update Nasdaq listing update

Yuyu Pharma is celebrating the 5th anniversary of the launch of its first generic hypertriglyceridemia

Performance BioFilaments Inc. is pleased to announce the availability of high performance nanofibrillated cellulose (NFC) starting in 2021.

On February 7, 2020 , the Securities and Exchange Commission (SEC) issued an Order of Suspension of Trading (the “SEC Order”), temporarily suspending trading in Aethlon Medical, Inc. (“Aethlon” or the “Company”) stock for a period of ten days. The SEC Order stated that the suspension was due to concerns regarding the

The 72-bed Phoenix Center is the first all-pediatric VOCSN facility in New Jersey

Feb. 10, 2020 14:15 UTC CHICAGO--( BUSINESS WIRE )-- Paul K. Kearns, director of the U.S. Department of Energy’s (DOE) Argonne National Laboratory, has been selected for the 2020 Federal Laboratory Consortium (FLC) Laboratory Director of the Year award. The award honors laboratory directors who have made major contributions to the overall enhancement of technology transfer for economic development, including support of FLC activities, internal accomplishments, industry involvement

MINES & Associates (MINES) is seeking partnerships with on-site clinics to help improve behavioral health resources in communities where there is a need to increase access to high-quality care. Currently, access issues, provider scarcity, and long wait times are major barriers to care across the country.

Feb. 10, 2020 14:30 UTC Experienced executive to lead corneal disease clinical program for TTHX1114 SAN DIEGO--( BUSINESS WIRE )-- Trefoil Therapeutics today announced the appointment of Thomas M. Tremblay, RN, BSN to the newly created position of Vice President, Clinical Development. He brings to Trefoil more than 25 years of experience in pharmaceutical development across a variety of therapeutic areas. This press release features multimedia. View the full release he